Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

376
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
376
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

292
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
292
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

227
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
227
Drug Therapy01:28

Drug Therapy

109
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
109
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

496
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
496
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

286
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
286

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychotherapy Training Among Psychiatrists in Russia: A Cross-Sectional Study.

Consortium psychiatricum·2026
Same author

[Clinical and immunological relationships in patients with early schizophrenia].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

Comparison of Immune and Systemic Inflammation Parameters in Patients with a Depressive Episode in Bipolar Disorder and Major Depressive Disorder: A Scoping Review.

Consortium psychiatricum·2025
Same author

[Comorbidity of depression and dementia: epidemiological, biological and therapeutic aspects].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2024
Same author

[Metabolic syndrome and antipsychotic therapy of schizophrenia].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2024
Same author

The Modern Concept of Schizoaffective Disorder: A Narrative Review.

Consortium psychiatricum·2024

Related Experiment Video

Updated: Sep 30, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K

[Second-generation long-acting injectable antipsychotics in clinical practice].

N N Petrova1, E V Grigorieva2

  • 1Saint Petersburg State University, St. Petersburg, Russia.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|March 10, 2022
PubMed
Summary
This summary is machine-generated.

Second-generation long-acting injectable antipsychotics offer effective therapeutic strategies for managing paranoid schizophrenia relapse. This study examines their use in combination therapy and during medication changes.

Keywords:
anti-relapse therapyclinical practiceschizophreniasecond-generation long-acting injectable antipsychotics

More Related Videos

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.7K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.0K

Related Experiment Videos

Last Updated: Sep 30, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.7K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.0K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Paranoid schizophrenia requires long-term management to prevent relapse.
  • Treatment challenges include adherence and managing side effects.
  • Second-generation antipsychotics offer improved side effect profiles.

Purpose of the Study:

  • To illustrate therapeutic tactics using second-generation long-acting injectable antipsychotics (SGA-ILAs) in paranoid schizophrenia.
  • To present research data supporting these treatment approaches.
  • To discuss combination therapy and medication switching strategies.

Main Methods:

  • Case study analysis of 5 patients with paranoid schizophrenia.
  • Review of clinical data and treatment outcomes.
  • Discussion of pharmacological principles for SGA-ILAs.

Main Results:

  • SGA-ILAs demonstrated effectiveness in managing different stages of paranoid schizophrenia.
  • Combination therapy and strategic medication replacement were successful.
  • Specific therapeutic tactics for relapse prevention were identified.

Conclusions:

  • Second-generation long-acting injectable antipsychotics are valuable tools for anti-relapse therapy in paranoid schizophrenia.
  • Flexible combination and switching strategies enhance treatment efficacy.
  • Clinical case examples support the use of SGA-ILAs in complex treatment scenarios.